In the United States, cancer is the second leading cause of death. In 2015, cancer claimed the lives of 595,930 people, equivalent to 22% of all deaths in the United States, as the CDC pointed out. This number is still rising, and it is estimated that cancer will kill more than 600,000 people last year before the end of 2017. According to data from the Health Care Research and Quality Institute, in 2014, the United States spent $87.8 billion on health care services provided by cancer. Genetic screening can help patients fight the disease. Early detection of cancer helps to allocate appropriate treatment and improve survival rates. Early disease detection can be used for various malignant tumors. According to data from the National Institutes of Health, genetic testing for susceptibility and early detection has actively adjusted the survival rate of various cancer growth by 35%. Breast cancer specialist in Delhi NCR provides a variety of positive results, such as improved survival rates and possible reduction of health care costs for patients and providers.
What is genetic screening?
Genetic testing is a medical screening that can identify changes in genes, chromosomes, or proteins. The findings found in genetic testing can confirm or rule out suspicious genetic diseases, or help determine a person’s chances of developing or passing on a genetic disease. There are currently more than 1,000 genetic tests in use.
Improve results
The basic goal is to distinguish the evidence of the highest-risk cancer population and to screen patients for early growth cancer to reduce mortality. Appropriate early screening may reduce mortality and provide patients with the possibility of prolonging and improving the quality of life. For example, breast cancer is one of the main sources of death in women with malignant tumors. The insights provided by the National Cancer Institute indicate that women who receive standard mammograms reduce the risk of death by 15% to 20%. Generally, screening consistency is low, which means that the number of people who should undergo a specific growth test is not ideal. For example, the CDC in 2014 showed that only 65.7% of patients over the age of 50 were screened for colon malignancies, while 27.3% of patients were screened completely. Researchers at the University of Michigan found that high-risk populations screened for colon cancer can prevent 90% of cancer diagnoses. According to the CDC, 9 out of 10 patients with colon growth found through normal screening are still alive 5 years after the initial diagnosis. In addition, patients with malignant tumors participating in the combat action plan, such as lifestyle adjustments and smoking cessation, can obtain reduced out-of-pocket expenses and medical benefit premiums. In some cases, early detection and treatment before metastasis can also positively change the treatment and outcome.
New genetic screening test is coming
Researchers at Johns Hopkins University in Baltimore, Maryland have led another malignant tumor identification strategy called target error-correcting sequencing. It can even be used to identify the lowest levels of circulating tumor DNA, which are usually found in early-growing tumors. During the examination, 200 samples were collected from people with colorectal cancer, breast cancer, ovarian cancer, and lung cancer, distinguishing 62% of stage I and II tumors. It is also worth mentioning that no false positives were found among the 44 healthy people who were tested.
Oncologist Dr. Dodul Mondal is a Cancer Specialist that has an interest in DNA and Genetic Testing specifically Best Surgical Oncologist in Delhi.